This morning Vancouver, Canada-based specialty medical device company Neovasc Inc. (NVCN:NASDAQ), which develops, manufactures and markets products for the cardiovascular marketplace, announced that "it has submitted a Premarket Approval application (PMA) to the U.S. Food and Drug Administration (FDA) for its Neovasc Reducer™ ("Reducer") medical device for the treatment of refractory angina." The firm noted that that the submission also included a request for an Advisory Panel meeting.
The company's President and CEO Fred Colen commented, "This submission marks an important milestone in our effort to bring Reducer to the U.S. market, where it is estimated that there are up to 1.8 million patients with refractory angina...These patients have traditionally had no options – they are either unsuitable for revascularization or continue to suffer with angina following revascularization procedures. The Reducer provides potential relief of angina symptoms by altering blood flow within the myocardium of the heart and increasing the perfusion of oxygenated blood to ischemic areas of the heart muscle."
The company advised that "the PMA for Reducer includes clinical data from the COSIRA 104 patient randomized, double-blind, sham-controlled trial, the ongoing REDUCER-I European Post-Market study, with over 200 patients currently enrolled with up to 5 years of follow-up, and supportive clinical evidence from multiple peer reviewed publications on Reducer."
The firm explained that refractory angina is a painful and debilitating condition that affects millions of patients worldwide. The condition occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle despite treatment with standard revascularization or cardiac drug therapies. The company claims that "the Reducer provides relief of angina symptoms by altering blood flow within the myocardium of the heart and increasing the perfusion of oxygenated blood to ischemic areas of the heart muscle and that placement of the Reducer is performed using a minimally invasive transvenous procedure."
Neovasc is headquartered in Vancouver, British Columbia, and describes itself as "a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina." The firm's products include the Tiara technology in development for the transcatheter treatment of mitral valve disease and the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara transcatheter device is designed to treat mitral regurgitation as a result of mitral heart valve disease, an often severe condition that can lead to heart failure and death. The Neovasc Reducer is a percutaneous treatment for refractory angina, a condition which affects millions worldwide. Though not yet commercially approved in the U.S., the company received Breakthrough Device designation for the Neovasc Reducer in October 2018 from the FDA.
Neovasc has a market capitalization of about $30 million with approximately 7.65 million shares outstanding. NVCN shares opened greater than 100% higher today at $7.99 (+$4.06, +103.31%) over yesterday's closing price of $3.93. The stock has traded today between $6.11 and $8.65 per share and is currently trading at $7.09 (+$3.16, +80.41%).[NLINSERT]
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.